Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 3
1990 1
1992 1
1997 1
2000 2
2001 3
2003 1
2005 1
2007 1
2011 2
2012 2
2013 1
2016 2
2018 2
2019 2
2020 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
Hirschfield GM, Shiffman ML, Gulamhusein A, Kowdley KV, Vierling JM, Levy C, Kremer AE, Zigmond E, Andreone P, Gordon SC, Bowlus CL, Lawitz EJ, Aspinall RJ, Pratt DS, Raikhelson K, Gonzalez-Huezo MS, Heneghan MA, Jeong SH, Ladrón de Guevara AL, Mayo MJ, Dalekos GN, Drenth JPH, Janczewska E, Leggett BA, Nevens F, Vargas V, Zuckerman E, Corpechot C, Fassio E, Hinrichsen H, Invernizzi P, Trivedi PJ, Forman L, Jones DEJ, Ryder SD, Swain MG, Steinberg A, Boudes PF, Choi YJ, McWherter CA; ENHANCE Study Group*. Hirschfield GM, et al. Hepatology. 2023 Aug 1;78(2):397-415. doi: 10.1097/HEP.0000000000000395. Epub 2023 Apr 6. Hepatology. 2023. PMID: 37386786 Free PMC article. Clinical Trial.
Mortality in Russia.
Ogurtsov PP, Nuzny VP, Garmash IV, Moiseev VS. Ogurtsov PP, et al. Lancet. 2001 Aug 25;358(9282):669-70. doi: 10.1016/S0140-6736(01)05803-2. Lancet. 2001. PMID: 11545084 No abstract available.
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.
Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, Shiffman ML, Yurdaydin C, Dalgard O. Sulkowski MS, et al. Among authors: ogurtsov p. Nat Rev Gastroenterol Hepatol. 2011 Apr;8(4):212-23. doi: 10.1038/nrgastro.2011.21. Epub 2011 Mar 8. Nat Rev Gastroenterol Hepatol. 2011. PMID: 21386812 Review.
Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
Isakov V, Paduta D, Viani RM, Enejosa JV, Pasechnikov V, Znoyko O, Ogurtsov P, Bogomolov PO, Maevskaya MV, Chen X, Shulman NS. Isakov V, et al. Among authors: ogurtsov p. Eur J Gastroenterol Hepatol. 2018 Sep;30(9):1073-1076. doi: 10.1097/MEG.0000000000001166. Eur J Gastroenterol Hepatol. 2018. PMID: 29762255 Clinical Trial.
27 results